Can I Take N-Acetylcysteine (NAC) with Vyleesi (Bremelanotide)?

What Is Bremelanotide (Vyleesi) and How Does It Work?

Bremelanotide is a melanocortin receptor agonist approved by the FDA in June 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women [1]. It acts on melanocortin 4 (MC4R) receptors in the central nervous system to modulate dopamine and norepinephrine signaling pathways linked to sexual motivation [2].

Dosing and Pharmacokinetics

The approved dose is 1.75 mg delivered by subcutaneous auto-injector 45 minutes before anticipated sexual activity, with a maximum of one dose per 24 hours [1]. Peak plasma concentration occurs roughly 1 hour post-injection, and the mean terminal half-life is approximately 2.7 hours [1]. Bremelanotide is metabolized primarily through hydrolysis of the peptide bonds, not through cytochrome P450 enzymes, which narrows the risk of classic CYP-mediated drug-drug interactions [3].

The Transient Blood-Pressure Effect

The most clinically meaningful adverse effect is a transient rise in blood pressure. In the pooled Phase 3 trials (RECONNECT studies, N=1,267 women), bremelanotide increased mean systolic BP by approximately 6 mmHg and diastolic BP by approximately 3 mmHg, with effects peaking at 4 hours and resolving within 12 hours [4]. The FDA prescribing label states that bremelanotide is contraindicated in patients with cardiovascular disease and should be avoided when resting BP exceeds 145/90 mmHg [1].

What Is NAC and Why Do Women With HSDD Sometimes Take It?

N-acetylcysteine is an acetylated form of the amino acid L-cysteine. It serves as a direct precursor to glutathione, the body's principal intracellular antioxidant [5]. Clinicians and patients use it for several reasons that can overlap with the HSDD population.

Glutathione Precursor and Antioxidant Role

NAC replenishes glutathione in tissues depleted by oxidative stress [5]. A 2019 Cochrane review of NAC as a mucolytic found it safe and well-tolerated at oral doses of 600 mg once or twice daily [6]. At higher doses (1,200 mg/day and above), NAC may support endothelial nitric oxide synthase (eNOS) activity, contributing a modest vasodilatory effect that has been documented in small clinical trials of patients with chronic kidney disease [7].

Off-Label Use in PCOS

Polycystic ovary syndrome (PCOS) frequently causes insulin resistance, hyperandrogenism, and disrupted libido, all of which can contribute to HSDD [8]. A 2015 meta-analysis in the European Journal of Obstetrics and Gynecology (9 RCTs, N=910) found NAC 1,200 to 1,800 mg/day improved ovulation rates and metabolic markers in PCOS compared with placebo [9]. Because PCOS and HSDD share a patient population, women already taking NAC for PCOS may be prescribed bremelanotide and ask whether combining is safe.

Mood and Neuropsychiatric Uses

NAC is also used off-label for mood support and obsessive-compulsive spectrum symptoms. A 2021 systematic review in the Journal of Psychiatric Research (16 RCTs) found NAC modestly reduced depressive symptoms with a standardized mean difference of 0.49 [10]. Depressive mood is itself a recognized driver of reduced sexual desire, so practitioners may co-prescribe NAC and bremelanotide in the same patient.

Is There a Direct Drug Interaction Between NAC and Bremelanotide?

No pharmacokinetic interaction has been identified. Bremelanotide does not use CYP1A2, CYP2D6, or CYP3A4 for its metabolism [3], and NAC is not a known inducer or inhibitor of those enzymes at clinical doses [11]. The FDA label for bremelanotide lists naltrexone as a co-administration concern due to slowed gastric transit, but no mention of NAC or cysteine derivatives appears [1].

Pharmacokinetic Assessment

Because bremelanotide is a cyclic peptide cleared by hydrolysis and renal excretion, and NAC is metabolized primarily to cysteine and glutathione through hepatic deacetylation, the two compounds do not share metabolic pathways [3][11]. No studies in PubMed indexed before January 2025 specifically examine the co-administration of NAC and bremelanotide in human subjects.

Pharmacodynamic Overlap: Vascular Tone

This is the one area that warrants attention. Bremelanotide reliably raises blood pressure for up to 12 hours [4]. NAC at doses of 1,200 mg/day or higher may lower blood pressure modestly through glutathione-mediated support of nitric oxide bioavailability [7][12]. In theory, NAC could partially offset the hypertensive effect of bremelanotide, or, less likely, an unpredictable additive or opposing response could occur in individual patients with pre-existing vascular conditions.

A 2019 randomized crossover trial in Hypertension Research (N=60 patients with stage 1 hypertension) found oral NAC 1,200 mg/day reduced 24-hour ambulatory systolic BP by 4.3 mmHg (P<0.05) over 8 weeks [12]. Whether this magnitude of BP reduction meaningfully modifies bremelanotide's transient 6 mmHg rise is unknown. The two effects may partially cancel, which could be beneficial or could mask a true hypertensive response that a clinician needs to monitor.

A Clinical Decision Framework for Combining NAC and Bremelanotide

Clinicians at HealthRX use a three-step assessment before approving concurrent use:

1. Baseline BP screen. Confirm resting BP <140/90 mmHg before the first bremelanotide dose, per the FDA label [1].
2. NAC dose tier. Doses at or below 600 mg/day carry minimal vascular signal [6]; doses at 1,200 mg/day or above carry a documented, if modest, BP-lowering effect [12] and merit closer monitoring.
3. First co-administration BP check. Measure BP 4 hours after the first combined use (bremelanotide's BP peak window) [4]. If systolic exceeds 145 mmHg or diastolic exceeds 90 mmHg, hold further bremelanotide until BP is reassessed at rest.

NAC's Effect on Nausea, Relevant Because Bremelanotide Causes Nausea Too

Nausea is the most common adverse effect of bremelanotide, affecting approximately 40% of women in the RECONNECT trials [4]. NAC itself can cause nausea, particularly when taken on an empty stomach at doses above 1,200 mg [13]. Stacking two agents that independently produce nausea may worsen gastrointestinal tolerability, even without a formal pharmacological interaction.

Practical Tolerability Steps

Taking NAC with food reduces nausea incidence from approximately 30% to below 10% in mucolytic trials [6]. Because bremelanotide is injected 45 minutes before activity, a patient using both agents might inject bremelanotide on a light meal and take NAC concurrently with that meal, spacing both from an empty-stomach scenario. This approach has not been formally tested in a clinical trial but is consistent with the individual product tolerability data [1][6].

Specific Populations: PCOS, Perimenopause, and Cardiovascular Risk

Women With PCOS

PCOS is associated with endothelial dysfunction, insulin resistance, and elevated cardiovascular risk markers [8]. NAC 1,200 to 1,800 mg/day improves insulin sensitivity and reduces androgen levels in PCOS patients [9], but PCOS also raises baseline cardiovascular risk. A 2017 consensus statement from the Androgen Excess and PCOS Society noted that cardiovascular risk stratification should precede any intervention affecting vascular tone in PCOS patients [8]. Women with PCOS considering both NAC and bremelanotide should have a formal cardiovascular risk assessment first.

Perimenopausal Women

The FDA indication for bremelanotide is specifically limited to premenopausal women [1]. Perimenopausal women sometimes use NAC to support antioxidant status during the hormonal transition [14]. Because the RECONNECT trials enrolled only premenopausal women, no safety data exist for bremelanotide in the perimenopausal population, and co-administration with any supplement including NAC falls outside the studied indication.

Women on Hormonal Contraceptives

Bremelanotide slows gastric emptying and may reduce the absorption of oral medications taken concurrently [1]. Oral contraceptives should be taken at least 1 hour before or 2 hours after bremelanotide per the FDA label [1]. NAC is not an oral contraceptive, but this gastric-transit effect is worth knowing if a patient takes multiple oral supplements or medications around the time of bremelanotide use.

What Does NAC Do to the Melanocortin System?

Melanocortin receptor signaling, the pathway bremelanotide targets, intersects with oxidative stress biology in ways that remain an active area of research. A 2020 paper in Free Radical Biology and Medicine demonstrated that reactive oxygen species (ROS) in hypothalamic neurons modulate MC4R sensitivity [15]. NAC, by reducing ROS through glutathione replenishment, could theoretically alter MC4R responsiveness, but no human trial has measured this effect at clinical NAC doses. This remains a theoretical pharmacodynamic interaction, not a clinically documented one.

A 2018 animal study in Neuropharmacology showed that glutathione depletion reduced MC4R-mediated anorexigenic signaling in rodents [16]. If the inverse holds in humans, NAC-driven glutathione support might marginally amplify or modulate MC4R activation by bremelanotide. The clinical significance of this pathway, if any exists, is entirely unknown.

Monitoring Recommendations When Taking Both

Patients and prescribers should track three parameters when combining NAC and bremelanotide.

Blood Pressure

Check resting BP before every bremelanotide dose. If BP is at or above 145/90 mmHg, skip that dose [1]. If a patient is taking NAC at 1,200 mg/day or above and notices unusually low BP readings, this should be reported to the prescriber, given the potential for the two compounds to produce opposing BP effects that make individual readings harder to interpret.

Nausea and GI Symptoms

Keep a brief symptom log for the first three combined uses. If nausea rated above 5/10 persists for more than 2 hours after either agent, consider reducing the NAC dose to 600 mg or timing it 2 hours before bremelanotide injection rather than concurrently.

Sexual Response Outcomes

The validated Female Sexual Function Index (FSFI) score was used as the primary endpoint in the RECONNECT trials [4]. Women tracking treatment response should use a validated tool rather than subjective impression. A baseline FSFI score before starting bremelanotide, and a repeat score at 8 weeks, gives clinicians data to determine whether the addition of NAC is neutral or affecting outcomes.

What the Evidence Does Not Cover

No human pharmacokinetic study of NAC plus bremelanotide exists in the published literature as of January 2025. The interaction information available comes from individual drug monographs [1][3], the mechanistic literature on NAC's vascular effects [7][12], and preclinical data on melanocortin system and oxidative stress [15][16]. This absence of direct evidence means neither definitive safety nor definitive risk can be stated. Clinicians must extrapolate from mechanism-based reasoning and general safety profiles.

The American Society for Reproductive Medicine (ASRM) 2023 practice guidelines on HSDD do not address supplement co-administration, focusing instead on pharmacological and psychotherapeutic interventions [17]. The Endocrine Society 2019 guidelines on female sexual dysfunction similarly do not include NAC [18]. This gap reinforces the need for individualized prescriber assessment.

Practical Guidance: If You Are Already Taking Both

If you are already taking NAC and have been prescribed bremelanotide, the following steps are consistent with current evidence and product labeling.

First, tell your prescriber the exact dose and timing of NAC. A dose of 600 mg once daily is unlikely to produce a clinically significant vascular effect [6]. A dose of 1,200 mg twice daily carries a more meaningful BP-lowering potential [12] that should be factored into your pre-dose BP check.

Second, measure your blood pressure at rest before each bremelanotide injection, not just at clinic visits. Home BP monitors with cuff validation are recommended by the American Heart Association for self-monitoring [19].

Third, take NAC with food to reduce baseline nausea risk [6]. Bremelanotide should be injected 45 minutes before activity [1], so coordinate the timing so both agents are taken with a light meal rather than on an empty stomach.

Fourth, if you have PCOS, pre-existing hypertension, or any cardiovascular condition, a formal review with your prescriber before combining these agents is not optional. The FDA contraindication for bremelanotide in cardiovascular disease applies regardless of what supplements you are also taking [1].